GSTM1 and chronic myelogenous leukemia, BCR-ABL1 positive: In a previous study including CML patients who were in DMR with imatinib 400 mg daily, a dose reduction to 300 mg daily resulted in a median Hb increase of 1 g/dL among the anemic patients32.